v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balances, at Beginning of period at Dec. 31, 2024 $ 408,964 $ 7 $ 843,920 $ 143 $ (435,106)
Balances, at Beginning of period (in shares) at Dec. 31, 2024   74,312,608      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exchange of common stock shares for pre-funded warrants (in shares)   (6,070,000)      
Stock-based compensation expense 4,378   4,378    
Exercise of stock options 236   236    
Exercise of stock options (in shares)   90,457      
Issuance costs for the shares issued under equity private placement (14)   (14)    
Net unrealized gain (loss) on marketable securities 277     277  
Net loss (30,389)       (30,389)
Balances, at End of period at Mar. 31, 2025 383,452 $ 7 848,520 420 (465,495)
Balances, at End of period (in shares) at Mar. 31, 2025   68,333,065      
Balances, at Beginning of period at Dec. 31, 2025 478,559 $ 8 1,075,487 621 (597,557)
Balances, at Beginning of period (in shares) at Dec. 31, 2025   81,376,449      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exchange of pre-funded warrants for common stock shares (in shares)   3,500,000      
Stock-based compensation expense 10,148   10,148    
Issuance of shares under at-the-market offering, net of issuance costs of $25 41,918   41,918    
Issuance of shares under at-the-market offering, net of issuance costs of $25 (in shares)   1,712,739      
Exercise of stock options $ 4,023   4,023    
Exercise of stock options (in shares) 747,767 743,783      
Net unrealized gain (loss) on marketable securities $ (1,081)     (1,081)  
Net loss (53,089)       (53,089)
Balances, at End of period at Mar. 31, 2026 $ 480,478 $ 8 $ 1,131,576 $ (460) $ (650,646)
Balances, at End of period (in shares) at Mar. 31, 2026   87,332,971